Caspase-2, a Novel Lipid Sensor under the Control of Sterol Regulatory Element Binding Protein 2


Updated information and services can be found at: http://mcb.asm.org/content/25/21/9621

**SUPPLEMENTAL MATERIAL**

Supplemental material

**REFERENCES**

This article cites 55 articles, 26 of which can be accessed free at: http://mcb.asm.org/content/25/21/9621#ref-list-1

**CONTENT ALERTS**

Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more»
Caspase-2, a Novel Lipid Sensor under the Control of Sterol Regulatory Element Binding Protein 2†

E. Logette,1 C. Le Jossic-Corcos,2‡ D. Masson,3 S. Solier,1 A. Sequeira-Legrand,1 I. Dugail,4 S. Lemaire-Ewing,5 L. Desoche,5 E. Solary,5 and L. Corcos1*

INSERM U517, IFR100, Faculté de Médecine, 7 bd. Jeanne de Arc, 21000 Dijon, France; Laboratoire de Biologie Moléculaire et Cellulaire, Faculté des Sciences Gabriel, 6 bd. Gabriel, 21000 Dijon, France; INSERM U498, IFR100, CHRU le Bocage, 7 bd. Jeanne de Arc, 21000 Dijon, France; and INSERM U465, Centre des Cordeliers, 15 rue de l’Ecole de Médecine, 75270 Paris, France

Received 22 April 2005/Returned for modification 18 May 2005/Accepted 16 August 2005

Caspases play important roles in apoptotic cell death and in some other functions, such as cytokine maturation, inflammation, or differentiation. We show here that the 5’-flanking region of the human CASP-2 gene contains three functional response elements for sterol regulatory element binding proteins (SREBPs), proteins that mediate the transcriptional activation of genes involved in cholesterol, triacylglycerol, and fatty acid synthesis. Exposure of several human cell lines to statins, lipid-lowering drugs that drive SREBP proteolytic activation, induced the CASP-2 gene to an extent similar to that for known targets of SREBP proteins. Adenoviral vector-mediated transfer of active SREBP-2 also induced expression of the CASP-2 gene and the caspase-2 protein and increased the cholesterol and triacylglycerol cellular content. These rises in lipids were strongly impaired following small interfering RNA-mediated silencing of the CASP-2 gene. Taken together, our results identify the human CASP-2 gene as a member of the SREBP-responsive gene battery that senses lipid levels in cells and raise the possibility that caspase-2 participates in the control of cholesterol and triacylglycerol levels.

Caspases belong to a large family of serine-aspartate proteases, which are primarily involved in the proteolysis of various substrates, including essential cellular proteins and procaspases themselves (8, 12). During apoptosis induction by various stresses, such as exposure to anticancer drugs or UV irradiation, procaspases undergo sequential activation steps that ultimately lead to cell dismantling and death (46). Caspases are often classified as initiators or executioners of the apoptotic program, in correlation with the length of their N-terminal prodomain (24). Some caspases, like caspase-1, do not, however, play major roles in apoptosis but support important physiological functions, in this case maturation of pro-interleukin 1β into active interleukin 1β, or play important—although less clearly defined—roles in lymphocyte proliferation (23) and differentiation of various cell types (48) (for a review, see references 13 and 42).

One of the caspases involved in apoptosis is caspase-2 (Casp-2), whose activation can precede mitochondrial permeabilization in some proapoptotic paradigms (26, 35, 37), an effect that appears to involve processing of thezymogen but not always the associated catalytic activity (38). In addition, caspase-2 has recently been shown to participate in the inflammatory response upon recruitment in a protein complex with TRAF-2 and RIP1 and induction of NF-κB and p38 mitogen-activated protein kinase activation (25). Two main caspase-2 isoforms may be synthesized. Caspase-2L is proapoptotic (6, 50), whereas caspase-2S can oppose some of the apoptotic effects triggered by caspase-2L (7, 50). However, we have recently shown that the Casp-2S isoform encoding mRNA is subjected to nonsense-mediated decay in many human cell types (47). Therefore, most of the biological activity of caspase-2 is likely to depend on expression of the long caspase-2L isoform. We have recently reported the isolation and initial analysis of the human CASP-2 gene promoter activity (27). This promoter region allows mRNA initiation from separate domains of the two main caspase-2 transcripts. The CASP-2L promoter region is much more active than the downstream CASP-2S promoter, in good correlation with the respective levels of the transcripts found in the majority of cells and tissues (50).

A survey of putative transcription factor binding sites within the 5’-flanking region of the CASP-2 gene revealed the presence of several sites that can be recognized by sterol regulatory element binding proteins (SREBPs). These sites are found in the promoter region of genes involved in lipid homeostasis, encoding enzymes involved in the cholesterol or triacylglycerol/phospholipid synthesis pathways, such as 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase or farnesyl diphosphate synthase (FPP synthase) (11), and the fatty acid synthase (FAS) (28) or low-density lipoprotein receptor (LDLr) (51) (for a review, see references 3, 19, and 40). SREBP proteins are endoplasmic reticulum (ER)- and nuclear membrane-bound 125-kDa transcription factors with a basic helix-loop-helix leucine zipper structure, involved in the maintenance of lipid homeostasis (17, 33, 44). Three major SREBP isoforms are known in humans, mice, and hamsters: SREBP-1a
and SREBP-1c are encoded by the same gene through the use of separate transcription start sites, whereas SREBP-2 is encoded by a distinct gene (22, 29). SREBP-1c, which harbors a short N-terminal acidic domain, is a much weaker transactivator than SREBP-1a and SREBP-2 (45). When sterol levels are low, i.e., in response to statins, HMG-CoA reductase inhibitors, the 125-kDa membrane-bound precursor form of SREBP is transported to the Golgi apparatus by a chaperone protein, the sterol cleavage activating protein, SCAP (2, 3, 21), which is both an escort protein and a sensor of sterol levels. Recently, two additional ER-bound proteins, Insig-1 and Insig-2, have been shown to control the transport of the SCAP-SREBP complex to the Golgi apparatus (for a review, see reference 36), where SREBPs are sequentially cleaved by the S1P and S2P proteases (3, 39), which leads to the release of the 68-kDa transcriptionally active N-terminal domain of the protein. This fragment dimerizes, migrates into the nucleus, helped by importin β (31, 32), and binds to sterol regulatory elements (SREs) or to E-box sequences to enhance transcription of target genes (3, 9). In addition to the sterol regulatory cleavage system, rapid degradation by the ubiquitin proteasome pathway (16) and a feed-forward regulation mediated by SREs present in the promoters of the SREBP-1a and SREBP-2 genes (1, 41) control SREBP activity in the nucleus. The three isoforms play partially different roles in lipid homeostasis. SREBP-1c and -1a are involved in fatty acid metabolism, and SREBP-1c appears to be a mediator of insulin/glucose signaling in lipogenesis (15), whereas SREBP-2 regulates both cholesterol and lipogenesis in vitro and in vivo (34).

The identification of several putative DNA binding sites for SREBP proteins in the promoter region of the human CASP-2 gene prompted us to investigate the possible roles of these sites in the regulation of CASP-2 gene expression. Our results demonstrate that the CASP-2 gene is a member of the SREBP-responsive gene battery in human cells. Strikingly, suppression of CASP-2 gene expression strongly reduced the increase in cellular lipid levels brought about by overexpression of SREBP-2. Thus, besides its role in cell death, caspase-2 activity may be required as part of the adaptive response of human cells to variations in cholesterol and triacylglycerol levels. The implication of these findings may be twofold. First, they support and extend the notion that disturbance of lipid homeostasis may play an important role in the sensing of apoptosis stimuli. Second, they might suggest new venues of investigation to address the mechanism underlying some lipid disorders.

**MATERIALS AND METHODS**

**Cell lines and culture.** Three human cell lines were used in this study: the HepG2 hepatoma cell line (American Type Culture Collection, Rockville, MD) as a representative liver cell line, strongly engaged in lipid synthesis, and the HeLa cervical carcinoma cell line and the HCT116 colon carcinoma cell line, representative of other cancer types (ECACC, Salisbury, United Kingdom). Cells were maintained in Eagle’s minimum essential medium supplemented with 10% (vol/vol) fetal calf serum for HeLa and HCT116 cells and in Dulbecco minimum essential medium plus Ham F10 medium (1:1) in the presence of 5% (vol/vol) fetal calf serum for HepG2 cells. Both media were supplemented with 2 mM L-glutamine, penicillin (100 U/ml), and streptomycin (100 μg/ml), and cells were cultured at 37°C in an atmosphere of 95% air and 5% CO2. All tissue culture compounds were purchased from BioWhittaker (Fontenay-sous-Bois, France).

For lovastatin treatment (Sigma-Aldrich, Saint-Quentin Fallavier, France), all cell lines were precultivated in 5% lipoprotein-deficient serum (Sigma-Aldrich) during 24 to 36 h. Lovastatin was dissolved in dimethyl sulfoxide. The final concentration of dimethyl sulfoxide did not exceed 0.5% (vol/vol), a concentration that did not induce any toxicity.

**Plasmid constructions.** Fragments from the promoter region of the human CASP-2 gene were inserted into the promoterless pGL3-basic vector (pGL3b; Promega, Charbonnières, France) or into the simian virus 40 (SV40) promoter-containing pGL3-promoter vector (pGL3-prom; Promega). Progressive deletion constructs of the CASP-2 gene 5'-flanking region were produced by PCR. Five-prime deletion constructs containing the CASP-2L transcription start site were inserted into pGL3b, and 3' deletion constructs were inserted into pGL3 pm, under the control of the SV40 promoter. All plasmids were purified with the “Nucleobond ax” extraction kit (Macherey-Nagel, Hoerdt, France) and verified by sequencing (Genome Express, Meylan, France). Sequences of the primers used (Prologis, France) are available in supporting information (see Table S1 in the supplemental material). These primers also contain KpnI and Xhol or BgIII restriction enzyme sites to facilitate subsequent cloning steps.

Plasmids encoding SREBP-1a and SREBP-2 transcriptionally active forms were a kind gift from T. F. Osborne (University of California, Irvine, CA). SREBP-1a and SREBP-2 expression was driven by the cytomegalovirus (CMV) promoter from the pCMV5 vector. The luciferase reporter vector for the proximal region of the LDL-receptor promoter (~171 to +57 inserted in pGL3b vector) was a kind gift from T. Huby (Inserm U551, Paris, France).

**Site-directed mutagenesis.** Point mutations were introduced with the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer’s instructions. Briefly, 40 ng of parental vectors was used with the relevant oligonucleotides, and PCR was performed for 18 cycles. The mutations were detected by sequencing. PCR primer sequences are available in the supplemental material (see Table S2 in the supplemental material).

**Adenoviral infections and plasmid and small interfering RNA (siRNA) transfections.** Overexpression of the mature form of SREBP-2 (nSREBP-2) or of a dominant-negative form of SREBP-2 (SREBP-2dn) (see Fig. S5 in the supplemental material) was obtained by infection with adenoviruses encoding the active transactivation domain (amino acids 1 to 475) or a truncated transactivation domain (amino acids 294 to 475) of human SREBP-2 fused to the green fluorescent protein (GFP) (Ad-S2n and Ad-S2dn, respectively). A GFP-only-containing adenovirus was used as a control (Ad-C). Cells were infected in serum-containing medium at a multiplicity of infection between 30 and 100 PFU/cell, depending on the experiment, and harvested after 28 h (HepG2) or 36 h (HeLa, HCT116).

Functional promoter activity of the 5'-flanking region of the CASP-2 gene was analyzed using pGL3 luciferase-reporter vectors. The pCMV β-galactosidase reporter vector (pCMV-βgal) was used as an internal control for normalization of transfection efficiencies. HepG2 cells were seeded into 24-well plates at the density of 200,000 cells/well 6 h before transfection by the Lipofectamine and lipopolis reagents (Invitrogen, Cergy-Pontoise, France) according to the manufacturer’s instructions. One hundred nanograms of each test plasmid, 20 ng of SREBP expression vector, and 20 ng of pCMV-βgal reporter vector were used for each transfection experiment. After 24 h, cells were harvested and harvested for β-galactosidase activity using a luciferase assay reagent (Promega) and a luminometer (Lumat LB 9507; EG&G Berthold) or using the β-galactosidase enzyme assay system (Promega) for β-galactosidase activity.

Sense and antisense SREBP-2 (sense-strand RNA sequence, 5'-AAACAGCGUGUAAU CCCAUUU-3') and caspase-2 (sense-strand RNA sequence, 5'-A AAACGUCUGUUGUAGCGAA-3') oligonucleotides correspond to positions 554 to 574 of the human SREBP-2 mRNA sequence (accession number U02031) and to positions 210 to 214 of the human caspase-2 mRNA sequence (accession number NM_032892). A scrambled caspase-2 siRNA was used as a control (sense-strand RNA sequence, 5'-UAUACGCGUAUUGAUAGAGA-3'). All oligonucleotides were purchased from Prologis. Sense and antisense oligonucleotides were annealed to generate the double-stranded siRNAs (SREBP-2, siS2; caspase-2, siC2; negative control, siNC) at the final concentration of 100 μM. Cells were plated in serum-containing medium (HeLa) or in serum-free medium (HCT116 and HepG2) without antibiotics the day before transfection and then transfected by adding 5 μl of oligofectamine (Invitrogen) to 5 μl of 20 μM siRNAs (final concentration, 100 nM). Cells were rinsed with medium 4 h after transfection and then maintained in culture for 2 days before analysis.

**RT-PCR and quantitative real-time PCR (Q-PCR) analysis.** Total RNA was isolated from the nucleiop RNA extraction kit (Macherey-Nagel). Five hundred nanograms of RNA was reverse transcribed and then amplified in one step with the QIAGEN OneStep reverse transcriptase PCR (RT-PCR) kit (QIAGEN, Courtabeuf, France) according to the manufacturer’s instructions. The identity of each PCR-generated product with its corresponding cDNA was confirmed by
sequencing. Sequences of sense and antisense primers used to amplify human cDNAs (Prolog), hybridization temperatures, and number of cycles performed are available in the supplemental material (see Table S3 in the supplemental material).

For Q-PCR, five hundred nanograms of total RNA was reverse transcribed using Moloney murine leukemia virus RT (Promega) in the presence of oligo(dT) according to the manufacturer’s instructions. Then, each sample was tested in duplicate and standardized to the β2-microglobulin mRNA. In brief, 0.5 μL cDNA, corresponding to about 5 ng, was used as a template with 1× buffer (Quantitect SYBR Green PCR master mix; Qiagen) and 0.3 μM of each primer (see Table S3 in the supplemental material) in a total reaction volume of 25 μL. Analyses were performed on an ABprism 7700 detector system (Applied Biosystems, Les Ulis, France) with the sequence detector system software.

Chromatin immunoprecipitation assays. Chromatin immunoprecipitation (ChIP) assays were performed using the ChIP-IT kit (Active Motif Europe, Villepinte, France) or rabbit anti-goat IgGs (1:5,000; Dako, Glosturp, Denmark). Blots were revealed using an Enhanced Chemioluminescence detection system (Bio-Rad, Ivry-sur-Seine, France) or mouse or goat anti-rabbit IgGs (1:10,000; Jackson ImmunoResearch Laboratories, West Grove, PA).

Several SREBP putative binding sites localize to the human CASP-2 gene promoter region. A survey of putative binding sites for transcription factors over a 5-kb region upstream from the first noncoding exon of caspase-2L revealed the presence of six putative SREBP binding sites. A schematic representation of the 5′ region of the CASP-2 gene and the location of the putative SREBP DNA binding sites is shown in Fig. 1A. All of these sites correspond to SREs, as identified in the genes coding for the LDLr, the HMG-CoA reductase, and the FPPs. Sites 2 (S2), 3 (S3), 5a (S5a), and 5b (S5b) are in close proximity with NF-Y and/or Sp1 DNA binding sites, a situation encountered in the SREBP binding regions from several responsive genes (30, 53). Most strikingly, S5a and S5b together with several Sp1 sites and one NF-Y site overlap within what we will refer to as the S5 complex (S5c). Such an organization is also found in the promoters of the mouse SREBP-1c (1), the human FAS (53), or the human HMG-CoA synthase (5) gene. These structural features prompted us to analyze further the role of the putative SREBP DNA binding sites in CASP-2 gene regulation.

SREBP proteins transactivate the human CASP-2 gene promoter. In order to analyze the contribution of the SREs to the regulation of CASP-2 gene expression, a set of 5′ and 3′ deletions of the CASP-2 gene promoter region was prepared and their functional activity was assayed in liver-derived HepG2 cells. The deletion constructs, as well as the proximal region of the LDLr promoter as a positive control, were then used in cotransfection assays with plasmids encoding the mature, transcriptionally active form of the SREBP-1a or SREBP-2 proteins. Both induced the activity of the 5′-deletion constructs up to 50-fold. The shorter fragment (d5′), which contained only the S5c sites, was induced by 10- to 20-fold, whereas the largest constructs showed stronger inductions (Fig. 1B).

As shown in Fig. 1C, the smallest 3′ deletion (d3′) was very highly responsive to either SREBP protein. By contrast, d3′ was
was unresponsive, and the larger d3 deletion was only weakly responsive, mostly to SREBP-2. This 3′-deletion analysis indicated that the putative SREBP S1 and S2 binding sites played little or no role in SREBP responsiveness, whereas the S3 site had a major impact on the response.

Mutations of the putative SREBP binding sites alter CASP-2 gene promoter activity. In order to analyze the functional activity of the putative SREBP binding sites, we prepared and tested mutants of each of these sites on 5′- and 3′-deletion constructs by cotransfection in HepG2 cells. As shown in Fig. 2A and B, mutation of the S4, S1, and S2 sites had no effect on SREBP transactivation by either SREBP isoform, in agreement with the results from 3′-deletion analyses (Fig. 1C). However, the transactivating potential of both SREBP isoforms was similarly influenced by mutations of the S3 and S5 sites. S3 site mutation reduced transactivation by SREBP-1a and -2 by 20 to 96%.

FIG. 1. 5′-flanking region of the human CASP-2 gene. (A) Sequence positions are numbered relative to the major translation initiation site (position 1) located in the first coding exon (E2) common to both caspase-2 isoforms. Both transcription initiation sites (+1 2L and +1 2S) and the corresponding first introns (I1C2L and I1C2S) are indicated. Gray boxes indicate the position of the first exons, specific for each Casp-2 mRNA. The six SRE sites are represented by black stars. Putative Sp1 and NF-Y sites are also shown. S5c designates a complex composed of four Sp1 sites, two juxtaposed SREs (S5a and S5b), and one NF-Y site. The sequence of each site is indicated, together with those of sites found in the promoters of bona fide SREBP target genes. (B and C) Each CASP-2 gene promoter fragment was prepared as described in Materials and Methods. Five-prime deletions (from d5′ to d5′) (B) were subcloned into the pGL3b vector and 3′ deletions (from d3′ to d3′) (C) in the pGL3 pm vector. Each SRE site is identified (S1 to S5c). HepG2 cells were transfected with each reporter vector (or with LDLr, empty pGL3b, or pGL3 pm vectors as controls) and cotransfected with expression vectors for the SREBP-1a (nSREBP-1a) or SREBP-2 (nSREBP-2) mature form. Luciferase activity was measured 24 h later and normalized to β-galactosidase activity. The bars represent inductions relative to basal luciferase activity without SREBP cotransfection. The values are the means (± standard deviations) of at least three independent experiments.
28% in the context of the CASP-2 gene promoter and by up to 57% in the context of the SV40 promoter. Mutation of both sites of the S5 complex abolished transactivation (Fig. 2A). To confirm the major implication of the S3 and S5c sites, we tested the effect of mutations of either site in the context of the largest CASP-2 gene promoter fragment. As shown in Fig. 2C, S3 site mutation slightly reduced transactivation by either SREBP-1a or -2, whereas mutations of S5c reduced it by up to 85%. Finally, mutations of both the S3 and S5c sites (m3/m5c) totally abolished transactivation by each SREBP. Similar results were obtained in HCT116 cells (data not shown). Taken together, these results demonstrate that most of the transcriptional activity of the CASP-2 gene observed upon overexpression of SREBP proteins may depend on the identified binding sites for these proteins, the S3 and especially the S5c sites.

Cholesterol-lowering drugs increase CASP-2 gene expression. In view of the positive regulation of the CASP-2 gene promoter by SREBP proteins, we sought to determine whether the endogenous gene could be regulated via the lipid content of the cells. To this end, we looked at the effects of statins, HMG-CoA reductase inhibitors, on expression of target genes. Statins are known to trigger cholesterol depletion and to evoke a compensatory feedback mechanism that induces SREBP maturation and transactivation potential. We treated the human HepG2 hepatoma cell line, strongly engaged in lipid synthesis, with 50 μM lovastatin for 24 h to inhibit cholesterol synthesis. As shown in Fig. 3A, mRNA levels from bona fide SREBP-responsive genes, such as the HMG-CoA reductase, the FPPs, and the LDLr genes, were rapidly increased in response to lovastatin. Remarkably, the Casp-2 mRNA level was also increased to a comparable extent. As a control, the Casp-3 mRNA level remained unaffected. In addition, Western blot analysis from lovastatin-treated HepG2 cells showed a marked increase in the procaspase-2 protein level (Fig. 3B). Since statins are known to trigger SREBP-2 isoform maturation, rather than that of SREBP-1 (20, 43), we decided to focus on the putative role of SREBP-2 in the control of the endogenous CASP-2 gene. To this end, we looked at the effect of SREBP-2 gene silencing on the response of HepG2 cells to lovastatin. As shown in Fig. 3C, lovastatin treatment led to the induction of FAS, HMG-CoA red, and Casp-2 mRNAs by two- to threefold in cells transfected with control siRNA, whereas this effect was not observed in cells transfected with SREBP-2 siRNA (lane 4 versus lane 2), indicating that lovastatin-mediated induction of target genes was dependent on SREBP-2. Furthermore, SREBP-2 silencing also triggered a drop in Casp-2 (27%), HMG-CoA-Red (75%), and FAS (60%) mRNA levels compared to those of control cells (lane 3 versus lane 1), suggesting that SREBP-2 may also control basal transcription of these target genes. The Casp-3 mRNA level remained unchanged. These results strongly suggest that SREBP-2 mediates the positive effect of statins on the Casp-2 mRNA level.
SREBP-2 controls endogenous CASP-2 gene expression. In order to confirm the role of SREBP-2 in the control of CASP-2 gene expression, we looked at the effect of SREBP-2 mature form overexpression. HCT116 and HeLa cells were infected by an adenovirus encoding the transactivation domain of SREBP-2 fused to GFP (S2) or with a GFP-only-containing virus as a control. Both nSREBP-2 and procaspase-2L, but not procaspase-3, protein levels were increased in S2-infected cells (Fig. 4A). As shown in Fig. 4B, overexpression of nSREBP-2 allowed a strong increase of FAS mRNA and a 2- to 4.6-fold increase of LDLr and Casp-2 mRNAs, with no effect on the caspase-3 mRNA level. Furthermore, the silencing of SREBP-2 by a siRNA also triggered a drop in the procaspase-2 protein level (Fig. 4C). Finally, infection of HCT116 cells with a dominant-negative form of SREBP-2 (S2dn) led to a slight but consistent decrease of the Casp-2, LDLr, and FAS mRNA levels (see Fig. S5 in the supplemental material). These results strongly indicate that SREBP-2 controls the basal expression of the CASP-2 gene.

SREBP-2 binds to the S3 and S5 sites of the CASP-2 gene. In order to obtain direct evidence for the in vivo binding of the SREBP-2 protein to its cognate response elements from the endogenous CASP-2 gene, we used ChIP assays with HepG2 chromatin extracts. As shown in Fig. 5 (lane 4), in HepG2 naive cells, SREBP-2 bound the S3 and especially the S5 sites, albeit less strongly than to the FPP synthase response element. Following lovastatin treatment, however, binding of SREBP-2 on the S3 and especially the S5 sites was strongly increased (S3 and S5, lane 8 versus lane 4), similarly to the FPP site, but not on the S2 site used as a
negative control. The “no antibody” condition did not give any signal. Similar results after lovastatin treatment were obtained in HCT116 cells (see Fig. S6, lane 8 versus lane 4, in the supplemental material).

Inhibition of CASP-2 gene expression reduces cholesterol and triacylglycerol levels. In view of the positive response of the CASP-2 gene to SREBP-2 and to lipid-lowering drugs, we looked at the effect of CASP-2 gene silencing on lipid levels in HCT116 cells. As shown in Fig. S7A and B in the supplemental material, transfected double-stranded Casp-2 siRNAs (26) led to a strong decrease of caspase-2, but not caspase-3, immunostaining and levels in protein extracts. To determine the impact of SREBP overexpression on lipid levels in the cell, we first determined, by flow cytometry analysis, the lipid content of Nile Red-stained HCT116 cells infected with the SREBP-2 mature form-encoding adenovirus. As shown in Fig. 6A, SREBP-2 overexpression resulted in a large increase in lipid levels (panel 2). As expected, a siRNA against SREBP-2 fully prevented the lipid increase and even suppressed basal levels from 16% to 8% positive cells (panel 3 versus panel 1). Strikingly, a siRNA against Casp-2 reduced the SREBP-2-mediated increase in lipid levels by 50% (from 53% to 26.5%; panel 4 versus panel 2). To confirm these results, we used Oil Red O staining, which labels all neutral lipids (Fig. 6B). This analysis showed a strong color increase in SREBP-2-transduced HCT116 cells (panel 2 versus panel 1), an effect which was fully prevented in the presence of a SREBP-2 siRNA (panel 3) and partially, but significantly, decreased in the presence of Casp-2 siRNA (panel 4). Finally, the SREBP-2-induced increase in cholesterol (2.3-fold) and triacylglycerol (5-fold) cellular levels was almost fully prevented by SREBP-2 siRNA and was reduced by 30% to 50% with Casp-2 siRNA (Table 1). Western blot analysis confirmed that SREBP-2 siRNA was indeed able to reduce SREBP-2 protein levels (see Fig. S7C in the supplemental material). All of these observations were also made with HeLa cells (data not shown). Taken together, these results strongly suggest that caspase 2 might participate in SREBP-2-driven lipid synthesis and/or accumulation in human cells.

DISCUSSION

The results from the present study allowed us to identify, and to functionally characterize, the transactivation potential
of SREBP proteins for the \textit{CASP-2} gene promoter region. We identified six potential SRE binding sites, including one SRE-containing complex similar to that found in the promoter of bona fide SREBP-responsive genes (1, 5, 53). Transient transfection and mutational analysis demonstrated that the \textit{CASP-2} gene promoter is fully responsive to the SREBP-1a and -2 proteins and that the S3 and S5c sites are responsible for most of the activating potential of SREBPs. The evidence that SREBP proteins also regulate the endogenous \textit{CASP-2} gene is severalfold. First, treatment of HepG2 liver cells, which synthesize large amounts of lipids, with the cholesterol-lowering drug lovastatin, known to induce maturation of the SREBP-2 isoform, led to induction of the \textit{CASP-2} gene to a similar extent to that observed for several SREBP-responsive genes. Remarkably, the same effects were found in other cell lines, including HEK 293, HeLa, and HCT116, as well as with another statin, mevastatin, in all cell lines (data not shown). Second, ChIP analysis demonstrated SREBP-2 binding to the S3 and S5c sites, an effect that was strongly increased in response to statins. Third, the use of an adenoviral vector encoding the mature form of SREBP-2 allowed stimulation of \textit{CASP-2} gene expression to the same extent as, or even more than, that of reference genes. Fourth, siRNA-mediated silencing of the SREBP-2 gene decreased expression of the \textit{CASP-2} gene, together with that of other SREBP-2-dependent genes. Therefore, \textit{CASP-2} is a true SREBP-2 target gene.

In view of these findings, we wished to address the possibility that the controlled expression of the \textit{CASP-2} gene could be linked to a novel function of caspase-2, i.e., the control of lipid levels in cells. As expected, siRNA-mediated silencing of SREBP-2 abrogated the rise in lipids triggered by SREBP-2 overexpression. Much strikingly, however, this rise in cellular lipid levels was also strongly dampened by Casp-2 mRNA silencing. This observation strongly suggests that caspase-2 may participate in SREBP-2-driven lipid synthesis and/or accumulation in human cells.

How caspase-2 is connected to lipid biosynthesis pathways in human cells is unclear at this stage. Overexpression of pro-caspase-2L did not trigger any rise in lipids, nor did it lead to an improved response to SREBP-2 overexpression, which suggests an additional requirement of some limiting factor for caspase-2 activity, a situation that may not be symmetrical with caspase-2 silencing (data not shown). Indeed, caspase-2 function has been shown to depend on its recruitment within mac-

![FIG. 5. SREBP-2 binds to the S3 and S5 sites of the caspase-2 promoter. Chromatin was prepared from untreated HepG2 cells (−) or cells treated with 50 μM lovastatin (+) for 36 h. Cells were incubated with ALLN for the last 3 h before harvesting to stabilize the nuclear SREBP-2 form. Each cross-linked chromatin extract was incubated with anti-SREBP-2 antibody (S2), with negative control IgG (IgG), or without antibody (−). DNA extracted from each immunoprecipitate was analyzed by PCR using the relevant primers (see Materials and Methods; also see Table S4 in the supplemental material) to test the binding of SREBP-2 to the S2, S3, and S5 sites from the \textit{CASP-2} gene and on the SRE-binding sequences of the FPP synthase gene as a positive control. The input chromatin (I) corresponds to a 1:100 dilution of total DNA extracted prior to immunoprecipitation. One representative experiment of two independent experiments with similar results is shown. Optimization of PCR amplification parameters (PCR cycle numbers and input DNA amount) was performed in pilot experiments.](http://mcb.asm.org/issue/figs/fig5.png)

![FIG. 6. Casp-2 silencing reduces cellular lipid content. HCT116 cells were transfected with specific siRNAs (siS2 or siC2) or with a control siRNA (sineg) and infected 24 h later by Ad-C or Ad-nS2 adenoviruses (30 PFU/cell) for 36 h. (A) Total lipids of HCT116 cells were stained by Nile Red and detected by flow cytometry. The dotted vertical line sets the fluorescence limits obtained in absence of Nile Red (the percentage of positive cells is indicated in each case). The results from one representative experiment of three independent experiments with similar results are shown. The variation between experiments did not exceed 5%. (B) Neutral lipids were labeled by Oil Red O staining. The results from one representative experiment of three independent experiments with similar results are shown.](http://mcb.asm.org/issue/figs/fig6.png)
TABLE 1. Casp-2 silencing reduces cholesterol and triacylglycerol levels

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Total cholesterol (mmol/10⁶ cells)</th>
<th>i.f.</th>
<th>Triacylglycerols (mmol/10⁶ cells)</th>
<th>i.f.</th>
</tr>
</thead>
<tbody>
<tr>
<td>sineg + Ad-C</td>
<td>0.76 ± 0.17</td>
<td></td>
<td>52 ± 26</td>
<td></td>
</tr>
<tr>
<td>sineg + Ad-nS2</td>
<td>1.72 ± 0.63³</td>
<td>2.26</td>
<td>259 ± 120²</td>
<td>4.98</td>
</tr>
<tr>
<td>siS2 + Ad-nS2</td>
<td>0.89 ± 0.16e</td>
<td>1.17</td>
<td>44 ± 9e</td>
<td>0.84</td>
</tr>
<tr>
<td>siC2 + Ad-nS2</td>
<td>1.18 ± 0.35e</td>
<td>1.55</td>
<td>125 ± 34e</td>
<td>2.41</td>
</tr>
</tbody>
</table>

*HeLa cells were transfected with specific siRNAs (siS2 or siC2) or with a control siRNA (sineg) and infected 24 h later by Ad-C or Ad-nS2 adenoviruses (30 PFU/cell) for 36 h before measuring total cholesterol and triacylglycerol contents by colorimetric assays as described in Materials and Methods. The values are the means (± standard deviations) for five independent experiments.

*³ P < 0.01; significance level compared to result for sineg + Ad-C (Student's t test).

*e P < 0.05; significance level compared to result for sineg + Ad-nS2 (Student's t test).

*d P < 0.01; significance level compared to result for sineg + Ad-nS2 (Student's t test).

*e.f., induction factor versus control (sineg + Ad-C).

romolecular protein complexes, such as the so-called PIDDosome, in which protein partner stoichiometry might be tightly controlled (49). In addition, use of the VDVAD-fmk permeant caspase-2 inhibitor did not block the increased lipid levels induced by SREBP-2 in any of the cell lines (data not shown), which indicates that caspase-2 enzymatic activity could be dispensable. It was in fact recently shown that caspase-2 activity might not be required to fulfill its role as an apoptotic initiator caspase (10, 38) or its role in inflammation (25). If indeed caspase-2 catalytic activity is dispensable for enhancing the activation of lipid synthesis by SREBP-2, presumably caspase-2 function may be largely related to its ability to interact with other cellular macromolecules, either proteins or lipids (10). Alternatively, since the activity of caspase inhibitors in live cells may not be fully quantitative, their lack of effects in some experimental paradigms might not be a fully reliable indicator of caspase activity and therefore of caspase function.

As an initial attempt to try to understand how caspase-2 may be able to exert some control on lipid synthesis and/or accumulation, we looked at expression of SREBP-2 target genes following siRNA-mediated Casp-2 gene silencing. In all cases surveyed, i.e., for the HMG-CoA reductase, the LDLr, and the FAS genes, a slight but consistent 17 to 30% reduction in the stimulation brought about by SREBP-2 overexpression was observed (see Fig. S8 in the supplemental material). Such a pleiotropic effect might be best explained by an activity of caspase-2 on a regulatory step common to expression of all these genes. One immediate possibility might be that physiological levels of caspase-2 would be able to interfere with SREBP-2 function. For instance, enzymatically active caspase-2 could degrade SREBP-2 into a cleavage product that would drive better transcriptional activation. However, upon use of recombinant active caspase-2, we obtained no evidence that caspase-2 could cleave SREBP-2, whereas caspase-3 was able to do so (see Fig. S9 in the supplemental material), as previously reported (52). Alternatively, caspase-2 could degrade inhibitory transcription factors, thus activating cholesterol and/or triacylglycerol synthesis. One candidate protein is the ATF6 transcription factor, an ER stress-inducible protein that undergoes proteolysis by the same S1P and S2P proteases as SREBPs (54) and that has been shown recently to antagonize SREBP-2 activity upon direct interaction. Indeed, the nuclear form of ATF6 is able to form a complex with the SRE-bound nSREBP-2, which leads to a strong impairment of SREBP-2 transcriptional activity (55). A schematic model that summarizes our observations is presented in Fig. 7.

In order to analyze Casp-2 gene regulation in live animals, we turned to mice. However, we failed to observe any effect of cholesterol and statin treatments on Casp-2 mRNA level in mouse liver (L. Corcos, A. Roth, and U. Meyer, unpublished observations). In addition, microarray analysis of liver RNA from SREBP-overexpressing transgenic mice or from mice deficient in the SREBP activation pathway did not detect any effect of SREBPs on Casp-2 mRNA (18). In fact, the 5' flanking region of the mouse Casp-2 gene is strikingly different from the human sequence, with many fewer putative SREBP binding sites and a distinct organization. Because of such fundamental differences in the structure of the Casp-2 gene between humans and mice, mice might just not be appropriate for evaluating the influence of caspase-2 on cholesterol and triacylglycerol levels. A contribution of caspase-2 to lipid anabolism might thus be better searched for directly in humans.

In conclusion, in addition to its role in cell death and to the recently identified role in inflammation (25), caspase-2 appears to be a positive regulator of cholesterol and triacylglycerol homeostasis in human cells, which adds to the growing list of nonapoptotic functions of caspases (13). It is tempting to speculate that any condition that would dampen sterol levels could activate SREBP binding sites from the Casp-2 gene, which would then be turned on to provide either a direct trigger or an amplification loop aimed at restoring normal cholesterol or triacylglycerol levels. Depending on the activity of SREBP proteins, caspase-2 could thus act as a second-order sensor for satisfying the lipid demand.
ACKNOWLEDGMENTS

We thank A. Roth and U. Meyer for the in vivo mice experiment; T. Huby for his gift of the LDLr promoter construct; T. Osborne for his gift of SREBP-2 knockout plasmids; A. B. Aitchison for his comments and suggestions; P. Grimaldi, G. Lizard, and L. Lagrost for their critical reading and suggestions; and F. Ménetrier for his help with lipid staining.

E. Logette was a recipient of a fellowship from the Ministry of Research and Education. S. Solier was appointed by the University Hospital, Dijon. This work was supported by the Ligue Nationale Française contre le Cancer, the Conseil General de Bourgogne, and the INSERM.

REFERENCES


